Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 6, 2015CEO David Green To Speak on January 14, 2015
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially...
-
Dec 22, 2014
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially...
-
Nov 26, 2014
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant,...
-
Nov 6, 2014Conference Call To Be Held at 11:00 AM ET Today
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant,...
-
Oct 27, 2014Conference Call to Occur at 11:00 A.M. ET That Day
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially...
-
Oct 17, 2014
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant,...
-
Sep 5, 2014Entitles Company To Seven Years of Marketing Exclusivity If Device Approved by FDA
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant,...
-
Aug 8, 2014Conference Call To Be Held at 11:00 AM ET Today
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant,...
-
Aug 1, 2014Conference Call to Occur at 11:00 A.M. ET That Day
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially...
-
Jun 30, 2014A Leap of Faith: A Meredith Vieira Special” Focuses on Trachea Replacement Surgeries Made Possible by Company’s Technology
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially...
-
May 15, 2014CEO David Green to Discuss Company Performance and Upcoming Milestones
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially...
-
May 14, 2014Green Explains How HART-Trachea Scaffold and Bioreactor Are Used To Create Replacement Tracheas for Transplant
HOLLISTON, Mass.--(BUSINESS WIRE)--David Green, CEO of Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for...
-
May 12, 2014Dr. Mallika Marshall Reports From HART Headquarters and Lab
HOLLISTON, Mass.--(BUSINESS WIRE)--David Green, CEO of Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for...
-
May 8, 2014Conference Call to Be Held at 11:00 AM ET Today
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially...
-
May 1, 2014Conference Call to Occur at 11:00 A.M. ET That Day
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially...
-
Apr 16, 2014More Than 25 Years of Organ Transplant Research and Clinical Practice Expected to Lead HART Through Clinical Development of Regenerated Organs for Transplant
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially...
-
Apr 15, 2014Study Results by Dr. Paolo Macchiarini and Research Team Published in Nature Communications Research to Be Presented at the American Association for Thoracic Surgery (AATS) Annual Meeting 2014 in Toronto
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially...
-
Mar 27, 2014Green Discusses Creation of Regenerated Tracheas Using Company’s Technology
HOLLISTON, Mass.--(BUSINESS WIRE)--David Green, CEO of Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for...
-
Mar 21, 2014Article Focuses on Company’s Role in Creating Regenerated Organs for Transplant
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially...
-
Mar 14, 2014
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially...
-
Mar 7, 2014Conference Call To Be Held At 11:00 AM ET Today
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially...
-
Mar 3, 2014Conference Call to Occur at 11:00AM ET That Day
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially...
-
Feb 27, 2014CEO David Green To Speak on Company Progress and Goals on March 26, 2014
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially...
-
Feb 26, 2014TV Segment and Article Focus on Development of Bioreactors for Organ Regeneration
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially...
-
Feb 24, 2014Article Focuses on HART Spin-Off and Plans to Create Lab-Grown Organs for Human Transplant
HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially...
